PD-1 or PD-L1 antibodies could block the PD-1/PD-L1 pathway and positively regulate the activation and function of T lymphocytes, thereby inhibiting tumor immunity, enhancing antitumor immunity, and inhibiting tumor growth (3, 4). This evidence concerns the gene CD274 and neoplasm.